DaVita Inc. (DVA) is a leading U.S. provider of kidney dialysis and related clinical services for patients with chronic and end-stage kidney disease. Headquartered in Denver, Colorado, it operates thousands of outpatient dialysis centers, offers home-based modalities, and runs integrated kidney care and lab services. The company has a market capitalization of $11.72 billion, which makes it a “large-cap” stock.
DaVita’s shares reached a 52-week high of $247.49 on Aug. 3, but are down 25.8% from that level. DaVita’s stock is down 12.4% over the past three months as investors take profits after a strong rally and weigh near-term volume and mix headwinds. Meanwhile, the broader S&P 500 Index ($SPX) is up 5.4% over the past three months. Therefore, DVA has clearly underperformed over this period.